Interpace Diagnostics Group (NASDAQ:IDXG) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.
Volatility & Risk
Interpace Diagnostics Group has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
This table compares Interpace Diagnostics Group and Haemonetics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Interpace Diagnostics Group||$21.90 million||1.22||-$12.19 million||($0.43)||-1.63|
|Haemonetics||$967.58 million||5.94||$55.02 million||$2.39||46.91|
Haemonetics has higher revenue and earnings than Interpace Diagnostics Group. Interpace Diagnostics Group is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
This table compares Interpace Diagnostics Group and Haemonetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-53.75%||-34.69%||-24.37%|
This is a summary of recent ratings and target prices for Interpace Diagnostics Group and Haemonetics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||4||0||3.00|
Interpace Diagnostics Group currently has a consensus price target of $3.56, indicating a potential upside of 408.93%. Haemonetics has a consensus price target of $117.75, indicating a potential upside of 5.03%. Given Interpace Diagnostics Group’s higher possible upside, equities research analysts clearly believe Interpace Diagnostics Group is more favorable than Haemonetics.
Insider & Institutional Ownership
22.8% of Interpace Diagnostics Group shares are owned by institutional investors. Comparatively, 98.9% of Haemonetics shares are owned by institutional investors. 2.8% of Interpace Diagnostics Group shares are owned by insiders. Comparatively, 1.0% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Haemonetics beats Interpace Diagnostics Group on 9 of the 12 factors compared between the two stocks.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.